MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
11.78
-0.79 (-6.28%)
At close: Oct 30, 2026, 4:00 PM EDT
11.98
+0.20 (1.70%)
After-hours: Oct 30, 2026, 4:36 PM EDT
MoonLake Immunotherapeutics Employees
MoonLake Immunotherapeutics had 130 employees as of December 31, 2025. The number of employees increased by 30 or 30.00% compared to the previous year. That makes MoonLake Immunotherapeutics the 29,806th largest employer in the world and 3,787th in the United States.
Employees
130
Change (1Y)
30
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$2,028,200
Market Cap
1.00B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 30 | 30.00% |
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| MannKind | 592 |
| Janux Therapeutics | 113 |
| Inhibrx Biosciences | 110 |
| Cullinan Therapeutics | 109 |
| Rapport Therapeutics | 84 |
| SpyGlass Pharma | 76 |
| Seaport Therapeutics | 58 |
MLTX News
- 2 months ago - MoonLake price target raised to $50 from $45 at H.C. Wainwright - TheFly
- 2 months ago - MoonLake's psoriatic arthritis drug meets key goals in late-stage trial - Reuters
- 2 months ago - MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c) - TheFly
- 2 months ago - MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16 - TheFly
- 2 months ago - MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - MoonLake Immunotherapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - MoonLake Immunotherapeutics Quarterly report: Q2 2026 - Filings
- 4 months ago - MoonLake Immunotherapeutics 9M share Secondary priced at $20.00 - TheFly